The developer of high-affinity monoclonal antibodies for applications in clinical diagnostics, announced fantastic audited results for the year ended 30 June 2015. Pre-tax margins of over 70% and superb cash…
The UK creator and engineer of antibodies for applications in clinical diagnostics, which we commented on in April 2015, has announced a short yet highly positive trading update covering…
With 2014 seeing the highest number of new admissions to AIM since the glory days of 2007, and 2015 also looking encouraging for the junior market, it’s a good time…
Bioventix is a business engaged in the creation and engineering of antibodies. It was incorporated in 2003, and began trading on PLUS Market in 2010, before moving to AIM in…
Access the all latest company comments on Investor's Champion.
Not yet registered? It's free to register. Register now.
Register on Investor's Champion
Access the all latest company comments on Investor's Champion.
Premium Content
Premium content provides more in-depth information on fascinating investment stories and research to help make your money go further.
Access Premium Content through individual credits (we only want you to read what you are interested in) or through an annual subscription, which works out as only 25p per day – a small price to guide you through the investing maze!
Subscription
Gain access to all our excellent content for just £90 per year, that’s just 25p per day for financial freedom.
In depth coverage of many of the world’s great companies
Breaking news on potential upcoming disasters
Unique insights from our top research team
Credits
Get access to our premium content for as little as £3.20 per article.